BioRestorative Therapies
BRTX | NASDAQ
$1.37
-$0.12 (-8.05%)
At close: Nov 16, 2026, 3:59 PM ET
$1.39
+$0.02 (+1.46%)
After-hours:
Nov 16, 2026, 7:58 PM ET
BioRestorative Therapies Company Profile
Company profile explainedCompany Profile
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Key Executives
| Name | Position |
|---|---|
| Katharyn Field | President, CEO, Interim CFO, Treasurer & Secretary and Director |
| Mika Grasso | Interim CEO & Director |
| Anna Skowron | CFO & Treasurer |
| Crystal Romano | Head of Global Commercial Operations |
| Francisco J. Silva | VP of Research & Development, Secretary & Chief Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 8-K | Current Report |
| Sep 10, 2026 | 8-K/A | [Amend] Current Report |
| Sep 02, 2026 | 8-K | Current Report |
| Sep 02, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 14, 2026 | NT 10-Q | Filing |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 03, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 30, 2026 | 3 | Filing |
BioRestorative Therapies
| Country | United States |
| IPO Date | Dec 5, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Katharyn Field |
Contact Details
40 Marcus Drive Melville,
New York 11747 United States
Stock Details
| Ticker Symbol | BRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505497 |
| CUSIP Number | 090655705 |
| ISIN Number | US0906557055 |
| SIC Code | 8090 |
Add to Watchlist
Select watchlists to add or remove BRTX